Drug Trial Radar · NCT03270553
A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin
Last checked: Nov 20, 2026Latest source record: Oct 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Aug 31, 2017
Primary completion
Oct 7, 2017
Study completion Oct 7, 2017
Sponsor
- Lead sponsor
- Achaogen, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, Phase 1, open label, randomized, two-sequence, two-period, crossover study to evaluate the drug-drug interaction potential between plazomicin and metformin in healthy subjects.
Conditions
- Healthy Volunteers
Interventions
plazomicinDrug
single intravenous dose
metforminDrug
single oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics of metformin in plasmaTime frame: 9 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Site
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.